Vicadrostat by Boehringer Ingelheim International for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval

Vicadrostat is under clinical development by Boehringer Ingelheim International and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure).

FDA sends warning letter to defibrillator battery manufacturer

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

July 31, 2024

Acellera and Psivant partner on AI-driven drug discovery

January 30, 2025

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale | Psychedelic Invest

Wesana Health Holdings Inc. (CSE:WESA / OTCQB:WSNAF), today announced the successful closing of the sale by Wesana Health Inc. (“WHI”), a subsidiary of the Company,

July 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.